| Harald Sauthoff, MD | |
|
423 E 23rd St, New York, NY 10010-5011 | |
| (212) 686-7500 | |
| Not Available |
| Full Name | Harald Sauthoff |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 34 Years |
| Location | 423 E 23rd St, New York, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063466001 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 237917 (New York) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 237917 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Westchester Medical Center | Valhalla, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Westchester Medical Center Advanced Physician Services Pc | 3173660776 | 729 |
News Archive
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ.
"This G8 summit was, yet again, a missed opportunity for international leaders to make a real commitment to long-term food security and support for African and developing world farmers," Eva Clayton, a former member of Congress and former assistant director general of the U.N. Food and Agriculture Organization (FAO), writes in this post in the Huffington Post's "The World" blog.
Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.
Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.
› Verified 3 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ.
"This G8 summit was, yet again, a missed opportunity for international leaders to make a real commitment to long-term food security and support for African and developing world farmers," Eva Clayton, a former member of Congress and former assistant director general of the U.N. Food and Agriculture Organization (FAO), writes in this post in the Huffington Post's "The World" blog.
Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.
Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.
› Verified 3 days ago
| Entity Name | Westchester Medical Center Advanced Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912131392 PECOS PAC ID: 3173660776 Enrollment ID: O20091031000042 |
News Archive
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ.
"This G8 summit was, yet again, a missed opportunity for international leaders to make a real commitment to long-term food security and support for African and developing world farmers," Eva Clayton, a former member of Congress and former assistant director general of the U.N. Food and Agriculture Organization (FAO), writes in this post in the Huffington Post's "The World" blog.
Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.
Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Harald Sauthoff, MD 423 E 23rd St, 111h, New York, NY 10010-5011 Ph: (212) 686-7500 | Harald Sauthoff, MD 423 E 23rd St, New York, NY 10010-5011 Ph: (212) 686-7500 |
News Archive
The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).
Hospital patients admitted with malnutrition or who don't eat for several days are at greater risk of a prolonged hospital stay, according to a study published in CMAJ.
"This G8 summit was, yet again, a missed opportunity for international leaders to make a real commitment to long-term food security and support for African and developing world farmers," Eva Clayton, a former member of Congress and former assistant director general of the U.N. Food and Agriculture Organization (FAO), writes in this post in the Huffington Post's "The World" blog.
Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.
Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.
› Verified 3 days ago
Dr. Ravishankar Ramaswamy, MD, MS Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1440 Madison Avenue, New York, NY 10029 Phone: 212-659-8552 Fax: 212-860-9737 | |
Dr. Pietro Alessandro Ambrogio Canetta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, Ph4-124, New York, NY 10032 Phone: 212-305-5020 Fax: 212-305-6692 | |
Dr. Rakhshan Mahmood Chida, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 327 E 17th St, New York, NY 10003 Phone: 212-420-5690 | |
Charles D Resor, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, New York, NY 10032 Phone: 212-305-2913 | |
Dr. Jacqueline Yuey Lonier, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1150 Saint Nicholas Ave, New York, NY 10032 Phone: 212-851-5494 | |
Dr. Sharon Uralil, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-3293 | |
Diana Kantor, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 775 9th Ave, New York, NY 10019 Phone: 212-586-1550 |